A one-time $2.125 million gene therapy competes against two chronic SMN2 modifiers, and newborn screening now decides the winner at diagnosis.

Spinal muscular atrophy is a monogenic motor-neuron disease caused by biallelic loss of SMN1, with SMN2 copy number setting severity. Three FDA-approved agents address it by distinct mechanisms: nusinersen (Spinraza, Biogen), an intrathecal antisense oligonucleotide approved December 2016; onasemnogene abeparvovec (Zolgensma, Novartis), a one-time AAV9 gene therapy approved May 2019 for patients under two; and risdiplam (Evrysdi, Roche/PTC), a daily oral approved August 2020 for all ages and types.

The commercial contest turns on two forces. A single $2.125 million gene-therapy infusion competes against therapies billed for life, so payers weigh one-time cure-intent against chronic control based on age and SMN2 copy number. Newborn screening, added to the federal panel in 2018 and covering all 50 states by 2023, now moves roughly 300 new diagnoses a year into a pre-symptomatic window where gene therapy produces near-normal motor development.

The battleground has shifted from rescuing symptomatic infants to treating pre-symptomatic newborns.

Five questions this report answers:

Q1 - How do the three SMA mechanisms differentiate on route, dosing and one-time versus chronic treatment?

Q2 - What does universal newborn screening mean for the competitive map between gene therapy and chronic modifiers?

Q3 - How do one-time gene therapy and lifetime chronic therapy compare on total cost and payer positioning?

Q4 - Why does age under two gate eligibility for the one-time Zolgensma gene therapy?

Q5 - How many new SMA diagnoses does universal newborn screening identify pre-symptomatically each year?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SpinalMuscularAtrophy #US #CompetitiveIntelligence #AXLRx #RareDisease

Live report page:  https://axlrx.ai/spinal-muscular-atrophy/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/